Skip to main content
SpringerLink
Log in

Liposomes for Pulmonary Drug Delivery

  • Chapter
  • First Online:
Controlled Pulmonary Drug Delivery

Part of the book series: Advances in Delivery Science and Technology ((ADST))

Abstract

Liposomes have been widely used in pulmonary drug delivery for ­multiple applications including solubilization, sustained release, cellular and intracellular ­targeting, minimization of toxicity, and facilitation of absorption. In this chapter, formulation aspects, aerosolization, and an extensive overview of the use of pulmonary drug delivery of liposomes for disease and drug classes are provided. Specifically, this chapter examines liposomes from in vitro work to clinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rawat M, Singh D, Saraf S, Saraf S (2008) Lipid carriers: a versatile vehicle for proteins and peptides. Yakugaku Zasshi 128(2):269–280

    Article  PubMed  CAS  Google Scholar 

  2. Samad A, Sultana Y, Aqil M (2007) Liposomal drug delivery systems: an update review. Curr Drug Deliv 4:297–305

    Article  PubMed  CAS  Google Scholar 

  3. Weiner AL (1994) Liposomes for protein delivery: selecting manufacture and developmental processes. Immunomethods 4:201–209

    Article  PubMed  CAS  Google Scholar 

  4. Guo J, Ping Q, Zhang L (2000) Transdermal delivery of insulin in mice by using lecithin ­vesicles as carrier. Drug Deliv 7:113–116

    Article  PubMed  CAS  Google Scholar 

  5. Lenk RP, Janoff AS, Ostro MJ (1985) Novel multilayered lipid vesicles: Comparison of physical characteristics of multilamellar liposomes and stable plurilamellar vesicles. Biochemistry 24:2833–2842

    Article  PubMed  Google Scholar 

  6. Storm G, Crommelin DJA (1998) Liposomes: quo vadis? PSTT 1:19–31

    CAS  Google Scholar 

  7. Bangham AD (1972) Model membranes. Chem Phys Lipid 8:386–392

    Article  CAS  Google Scholar 

  8. Bangham AD, Standish MM, Watkins JC, Weissmann G (1967) The diffusion of ions from a phospholipid model membrane system. Protoplasma 63:183–187

    Article  PubMed  CAS  Google Scholar 

  9. Immordino ML, Dosio F, Cattel L (2006) Stealth liposomes: review of the basic science, rationale and clinical applications, existing and potential. Int J Nanomed 3:297–315

    Google Scholar 

  10. Seltzer SE (1989) The role of liposomes in diagnostic imaging. Radiology 171:19–21

    PubMed  CAS  Google Scholar 

  11. Rhodes BA (1976) Liposomes and vesicles: a new class of radiopharmaceuticals? J Nucl Med 17:1102–1103

    PubMed  CAS  Google Scholar 

  12. Gaspar MM, Bakowsky U, Ehrhardt C (2008) Inhaled liposomes – current strategies and future challenges. J Biomed Nanotechnol 4:1–13

    Article  Google Scholar 

  13. Geiger K, Gallagher ML, Hedley-White J (1975) Cellular distribution and clearence of aerosolized dipalmitoyl lecithin. J Appl Physiol 39:759–766

    Article  Google Scholar 

  14. Oyarzun MJ, Clements JA, Baritusso A (1980) Ventilation enhances pulmonary alveolar clearance of radioactive dipalmitoyl phosphatidylcholine in liposomes. Am Rev Respir Dis 121:709–721

    Article  Google Scholar 

  15. Oyarzun MJ, Clements J (1977) Ventilatory and cholinergic control of pulmonary surfactant in the rabbit. J Appl Physiol 43:39–45

    Article  Google Scholar 

  16. Pre J, Perret G, Bladier D (1983) Lecithin content estimate of human alveolar lining layer, comparison with mouse, rat and rabbit. Comp Biochem Physiol 76:393–395

    Article  Google Scholar 

  17. Mihalko PJ, Schreier H, Abra RM (1988) Liposomes: a pulmonary perspective. In: Gregoriadis G (ed) Liposomes as drug carriers. Wiley, NewYork, pp 679–694

    Google Scholar 

  18. Goerke J (1998) Pulmonary surfactant: functions and molecular composition. Biochim Biophys Acta 1408:79–89

    Google Scholar 

  19. Juliano RL, McCullough HN (1980) Controlled delivery of an anti-tumor drug, localized action of liposome encapsulated cytosine arabinoside administered via the respiratory system. J Pharmacol Exp Ther 214:381–387

    Google Scholar 

  20. Mizushima Y, Hoshi K, Aihara H, Kurachi M (1983) Inhibition of bronchoconstriction by aerosol of a lipid emulsion containing prostaglandin E1. J Pharm Pharmacol 35:397

    Google Scholar 

  21. Farr SJ, Kellaway IW, Parry-Jones D, Woolfrey SG (1985) The clearance of 99m Tc labelled liposomes from the lungs of volunteers. Proceed Intern Symp Control Rel Bioact Mater 12:219–220

    Google Scholar 

  22. Shek PN, Suntres ZE, Brooks JI (1994) Liposomes in pulmonary applications: physico­chemical considerations, pulmonary distribution and antioxidant delivery. J Drug Target 2:431–442

    Article  PubMed  CAS  Google Scholar 

  23. Ulrich AS (2002) Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep 22:129–150

    Article  PubMed  CAS  Google Scholar 

  24. Bridges PA, Taylor KMG (1998) Nebulizers for the generation of liposomal aerosols. Int J Pharm 173:117–125

    Article  CAS  Google Scholar 

  25. Zaru M, Mourtas S, Klepetsanis P, Fadda AM, Antimisiaris SG (2007) Liposomes for drug delivery to the lungs by nebulisation. Eur J Pharm Biopharm 67:655–666

    Article  PubMed  CAS  Google Scholar 

  26. Bi R, Shao W, Wang Q, Zhang N (2008) Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. J Drug Target 16:639–648

    Article  PubMed  CAS  Google Scholar 

  27. Shahiwala A, Misra A (2004) Pulmonary absorption of liposomal levonorgesterol. AAPS PharmSciTech 5:1–5

    Article  Google Scholar 

  28. Desai TR, Wong JP, Hancock REW, Finlay WH (2002) A novel approach to the pulmonary delivery of liposomes in dry powder form to eliminate the deleterious effects of milling. J Pharm Sci 91:482–491

    Article  PubMed  CAS  Google Scholar 

  29. Steckel H, Eskandar F (2003) Factors affecting aerosol performance during nebulisation with jet and ultrasonic nebulisers. Eur J Pharm Sci 19:443–455

    Article  PubMed  CAS  Google Scholar 

  30. Bridges PA, Taylor KMG (2000) An investigation of some of the factors influencing the jet nebulisation of liposomes. Int J Pharm 204:69–79

    Article  PubMed  CAS  Google Scholar 

  31. Elhissi AMA, Faizi M, Naji WF, Gill HS, And Taylor KMG (2007) Physical stability and aerosol properties of liposomes delivered using an air-jet nebuliser and a novel micropump device with large mesh apertures. Int J Pharm 334:62–70

    Article  PubMed  CAS  Google Scholar 

  32. Leung KKM, Bridges PA, Taylor KMG (1996) The stability of liposomes to ultrasonic nebulisation. Int J Pharm 145:95–102

    Article  CAS  Google Scholar 

  33. Gaspar MM, Gobbo O, Ehrhardt C (2009) Generation of liposome aerosols with the Aeroneb Pro and the AeroProbe nebulisers. J Liposome Res. doi: DOI: 10.1080/08982100903085150

    Google Scholar 

  34. Rau JL, Ari A, Restrepo RD (2004) Performance comparison of nebuliser designs: constant-output, breath-enhanced and dosimetric. Respir Care 49:174–179

    PubMed  Google Scholar 

  35. Leung K, Louca E, Coates AL (2004) Comparison of breath enhanced to breath actuated nebulisers for rate, consistency and efficiency. Chest 126:1619–1627

    Article  PubMed  Google Scholar 

  36. Nerbrink OL, Pagels J, Pieron CA, Dennis JH (2003) Effect of humidity on constant output and breath enhanced nebuliser designs when tested in the EN 13544-1 EC standard. Aerosol Sci Technol 37:282–292

    Article  CAS  Google Scholar 

  37. Moghimi SM, Szebini J (2003) Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonisation and protein binding properties. Prog Lipid Res 42:463–478

    Article  PubMed  CAS  Google Scholar 

  38. Anabousi S, Kleemann E, Bakowsky U, Kissel T, Schmehl T, Gessler T, Seeger W, Lehr CM, Ehrhardt C (2006) Effect of PEGylation on the stability of liposomes during nebulisation and in lung surfactant. J Nanosci Nanotechnol 6:3010–3016

    Article  PubMed  CAS  Google Scholar 

  39. Kleemann E, Schmehl T, Gessler T, Bakowsky U, Kissel T, Seeger W (2007) Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: Formulation aspects and stability. Pharm Res 24:277–287

    Article  PubMed  CAS  Google Scholar 

  40. Gilbert BE (1996) Liposomal aerosols in the management of pulmonary infections. J Aerosol Med 9:111–122

    Article  PubMed  CAS  Google Scholar 

  41. Pandey R, Khuller GK (2005) Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother 55:430–435

    Article  PubMed  CAS  Google Scholar 

  42. Gaspar MM, Cruz A, Fraga AG, Castro AG, Cruz ME, Pedrosa J (2008) Developments on drug delivery systems for the treatment of mycobacterial infections. Curr Top Med Chem 8:579–591

    Article  PubMed  CAS  Google Scholar 

  43. Chinmote G, Banerjee R (2008) Evaluation of antitubercular drug-loaded surfactants as inhalable drug-delivery systems for pulmonary tuberculosis. J Biomed Mater Res A 89:281–292

    Google Scholar 

  44. Conley J, Yang H, Wilson T, Blasetti K, Di Ninno V, Schnell G, Wong JP (1997) Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterisation and efficacy against Francisella tularensis infection in mice. Antimicrob Agents Chemother 41:1288–1292

    PubMed  CAS  Google Scholar 

  45. Wong JP, Yang H, Blasetti KL, Schnell G, Conley J, Schofield LN (2003) Liposome delivery of ciprofloxacin against Francisella tularensis infection. J Control Release 92:265–273

    Article  PubMed  CAS  Google Scholar 

  46. Gilbert BE, Six HR, Wilson SZ, Wyde PR, Knight V (1988) Small particle aerosols of enviroxime-containing liposomes. Antivir Res 9:355–365

    Article  PubMed  CAS  Google Scholar 

  47. Wyde PR, Six HR, Wilson SZ, Gilbert BE, Knight V (1988) Activity against rhinoviruses, toxicity and delivery in aerosol of enviroxime in liposomes. Antimicrob Agents Chemother 32:890–895

    PubMed  CAS  Google Scholar 

  48. Knight V, Gilbert B (1988) Antiviral therapy with small particle aerosols. Eur J Clin Microbiol Infect Dis 7:721–731

    Article  PubMed  CAS  Google Scholar 

  49. Gavalda J, Martin M, Lopez P, Gomis X, Ramirez J, Rodriguez D, Len O, Puigfel Y, Ruiz I, Pahissa A (2005) Efficacy of nebulised liposomal amphotericin B in treatment of experimental pulmonary aspergillosis. Antimicrob Agents Chemother 49:3028–3030

    Article  PubMed  CAS  Google Scholar 

  50. Gilbert BE, Wyde PR, Lopez-Berestein G, Wilson SZ (1994) Aerosolised amphotericin B-liposomes for treatment of systemic candida infections in mice. Antimicrob Agents Chemother 38:356–359

    PubMed  CAS  Google Scholar 

  51. Ruijgrok EJ, Vulto AG, Van Etten EW (2000) Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats. J Pharm Pharmacol 52:619–627

    Article  PubMed  CAS  Google Scholar 

  52. Gilbert BE, Wyde PR, Wilson SZ (1992) Aerosolised liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in mice. Antimicrob Agents Chemother 36:1466–1471

    PubMed  CAS  Google Scholar 

  53. Clark JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman L, Bonner DP (1991) Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 35:615–621

    PubMed  CAS  Google Scholar 

  54. Gondal JA, Swartz RP, Rahman A (1989) Therapeutic evaluation of free and liposome encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother 33:1544–1548

    PubMed  CAS  Google Scholar 

  55. Ruijgrok EJ, Vulto AG, Van Etten EW (2001) Efficacy of aerosolised amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J Antimicrob Chemother 48:89–95

    Article  PubMed  CAS  Google Scholar 

  56. Rao RD, Markovic SN, Anderson PM (2003) Aerosol therapy for malignancy involving the lungs. Curr Cancer Drug Targets 3:239–250

    Article  PubMed  CAS  Google Scholar 

  57. Anderson PM, Katsanis E, Leonard AS, Schow D, Loeffler CM, Goldstein MB, Ochoa AC (1990) Increased local antitumor effects of interleukin 2 liposomes in mice with MCA-106 sarcoma pulmonary metastases. Cancer Res 50:1853–1856

    PubMed  CAS  Google Scholar 

  58. Khanna C, Hasz DE, Klausner JS, Anderson PM (1996) Aerosol delivery of interleukin 2 liposomes is non-toxic and biologically effective: canine studies. Clin Cancer Res 2:721–734

    PubMed  CAS  Google Scholar 

  59. Khanna C, Anderson PM, Hasz DE, Katsanis E, Neville M, Klausner JS (1997) Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 79:1409–1421

    Article  PubMed  CAS  Google Scholar 

  60. Ten RM, Anderson PM, Zein NN, Temesgen Z, Clawson ML, And Weiss W (2002) Interleukin-2 liposomes for primary immune deficiency using the aerosol route. Int Immunopharmacol 2:333–344

    Article  PubMed  CAS  Google Scholar 

  61. Wittgen BP, Kunst PW, van der Born K, Peters GJ, Perez-Soler R, Metzheiser B, Nicholson S, Perkins W, Pilkiewicz F, Postmus PE (2006) Phase I study of aerosolised SLIT cisplatin in the treatment of patients with carcinoma of the lung. J Clin Oncol 24:7131

    Google Scholar 

  62. Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, Knight V (2001) Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 7:3258–3262

    PubMed  CAS  Google Scholar 

  63. Knight V, Koshkina NV, Waldrep JC, Giovanella BC, Gilbert BE (1999) Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother Pharmacol 44:177–186

    Article  PubMed  CAS  Google Scholar 

  64. Koshkina NV, Kleinerman ES, Waidrep C, Jia SF, Worth LL, Gilbert BE, Knight V (2000) 9-nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res 6:2876–2880

    PubMed  CAS  Google Scholar 

  65. Knight V, Kleinerman ES, Waldrep JC, Giovanella BC, Gilbert BE, Koshkina NV (2000) 9-nitrocamptothecin liposome treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice. Ann N Y Acad Sci 922:151–163

    Article  PubMed  CAS  Google Scholar 

  66. Zhang LJ, Xing B, Wu J, Xu B, Fang XL (2008) Biodistribution in mice and severity of damage in rat lungs following pulmonary delivery of 9-nitrocamptothecin liposomes. Pulm Pharmacol Ther 21:239–246

    Article  PubMed  CAS  Google Scholar 

  67. Gilbert BE, Seryshey A, Knight V, Brayton C (2002) 9-nitrocamptothecin liposome aerosol: lack of subacute toxicity in dogs. Inhal Toxicol 14:185–197

    Article  PubMed  CAS  Google Scholar 

  68. Verschraegen CF, Gilbert BE, Loyer E, Huaringa A, Walsh G, Newman RA, Knight V (2004) Clinical evaluation of the delivery and safety of aerosolised liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 10:2319–2326

    Article  PubMed  CAS  Google Scholar 

  69. Widera A, Norouziyan F, Shen WC (2003) Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. Adv Drug Deliv Rev 55:1439–1466

    Article  PubMed  CAS  Google Scholar 

  70. Anabousi S, Bakowsky U, Schneider M, Huwer H, Lehr CM, Ehrhardt C (2006) In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. Eur J Pharm Sci 29:367–374

    Article  PubMed  CAS  Google Scholar 

  71. Zhao M, Fernandez LG, Doctor A, Sharma AK, Zarbock A, Tribble CG, Kron IL, Laubach VE (2006) Alveolar macrophage activation is a key initiation signal for acute lung ischemia reperfusion injury. Am J Physiol Lung Cell Mol Physiol 291:L1018–L1026

    Article  PubMed  CAS  Google Scholar 

  72. Nakamura T, Abu-Dahab R, Menger MD, Schafer U, Vollmar B, Wada H, Lehr CM, Schafers HJ (2005) Depletion of alveolar macrophages by clodronate-liposomes aggravates ischemia-reperfusion injury of the lung. J Heart Lung Transplant 24:38–45

    Article  PubMed  Google Scholar 

  73. Leemans JC, Juffermans NP, Florquin S, van Rooijen N, Vervoordeldonk MJ, Verbon A, van Deventer SJ, van der Poll T (2001) Depletion of alveolar macrophages exerts protective effects in pulmonary tuberculosis in mice. J Immunol 166:4604–4611

    PubMed  CAS  Google Scholar 

  74. Chono S, Tanino T, Seki T, Morimoto K (2006) Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes. J Drug Target 14:557–566

    Article  PubMed  CAS  Google Scholar 

  75. Chono S, Tanino T, Seki T, Morimoto K (2007) Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification. J Pharm Pharmacol 59:75–80

    Article  PubMed  CAS  Google Scholar 

  76. Lambros MP, Bourne DWA, Abbas SA, Johnson DL (1997) Disposition of aerosolised liposomal amphotericin B. J Pharm Sci 86:1066–1069

    Article  PubMed  CAS  Google Scholar 

  77. Vyas SP, Quraishi S, Gupta S, Jaganathan KS (2005) Aerosolised liposome-based delivery of amphotericin B to alveolar macrophages. Int J Pharm 296:12–25

    Article  PubMed  CAS  Google Scholar 

  78. Vyas SP, Kannan ME, Jain S, Mishra V, Singh P (2004) Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm 269:37–49

    Article  PubMed  CAS  Google Scholar 

  79. Chono S, Tanino T, Seki T, Morimoto K (2008) Efficient drug delivery to alveolar macrophages and lung epithelial lining fluid following pulmonary administration of liposomal ciprofloxacin in rats with pneumonia and estimation of its antibacterial effects. Drug Dev Ind Pharm 34(10):1090–1096

    Article  PubMed  CAS  Google Scholar 

  80. Liu FY, Shao Z, Kildsig DO, Mitra AK (1993) Pulmonary delivery of free and liposomal insulin. Pharm Res 10:228–232

    Article  PubMed  CAS  Google Scholar 

  81. Huang YY, Wang CH (2006) Pulmonary delivery of insulin by liposomal carriers. J Control Release 113:9–14

    Article  PubMed  CAS  Google Scholar 

  82. Chono S, Fukuchi R, Seki T, Morimoto K (2009) Aerosolised liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary insulin delivery. J Control Release 137:104–109

    Article  PubMed  CAS  Google Scholar 

  83. Karathanasis E, Bhavane R, Annapragada AV (2006) Triggered release of inhaled insulin from the agglomerated vesicles: pharmacodynamic studies in rats. J Control Release 113(2):117–127

    Article  PubMed  CAS  Google Scholar 

  84. Hajos F, Stark B, Hensler S, Prassl R, Mosgoeller W (2008) Inhalable liposomal formulation of vasoactive intestinal peptide. Int J Pharm 357:286–294

    Article  PubMed  CAS  Google Scholar 

  85. Stark B, Andreae F, Mosgoeller W, Edetsberger M, Gaubitzer E, Koehler G, Prassl R (2008) Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation. Eur J Pharm Biopharm 70(1):153–164

    Article  PubMed  CAS  Google Scholar 

  86. Rubinstein I, Ikezaki H, Onyüksel H (2006) Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters. Int J Pharm 316(1–2):144–147

    Article  PubMed  CAS  Google Scholar 

  87. Laube BL (2005) The expanding role of aerosols in systemic drug delivery, gene therapy and vaccination. Respir Care 50:1161–1176

    PubMed  Google Scholar 

  88. Griesenbach U, Geddes DM, Alton EW (2006) Gene therapy progress and prospects: cystic fibrosis. Gene Ther 13:1061–1067

    Article  PubMed  CAS  Google Scholar 

  89. Schwarz LA, Johnson JL, Black M, Cheng SH, Hogan ME, Waldrep JC (1996) Delivery of DNA-cationic liposome complexes by small-particle aerosol. Hum Gene Ther 10:731–741

    Article  Google Scholar 

  90. Li SD, Huang L (2006) Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm 3:579–588

    Article  PubMed  CAS  Google Scholar 

  91. Durcan N, Murphy C, Cryan SA (2008) Inhalable siRNA: potential as a therapeutic agent in the lungs. Mol Pharm 5(4):559–566

    Article  PubMed  CAS  Google Scholar 

  92. Kleemann E, Dailey LA, Abdelhady HG, Gessler T, Schmehl T, Roberts CJ, Davies MC, Seeger W, Kissel T (2004) Modified polyethylenimines as non-viral gene delivery systems for aerosol gene therapy: investigations of the complex structure and stability during air-jet and ultrasonic nebulization. J Control Release 100(3):437–450

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Panoz Institute, Dublin, Ireland

    Carsten Ehrhardt

Authors
  1. Janani Swaminathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carsten Ehrhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carsten Ehrhardt .

Editor information

Editors and Affiliations

  1. , Pharmaceutics Division - PHR 4.214, University of Texas, University Station 1, Austin, 78712, USA

    Hugh D.C. Smyth

  2. Eshelman School of Pharmacy, Division of Molecular Pharmaceutics, University of North Carolina, Chapel Hill, 27599, North Carolina, USA

    Anthony J. Hickey

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Controlled Release Society

About this chapter

Cite this chapter

Swaminathan, J., Ehrhardt, C. (2011). Liposomes for Pulmonary Drug Delivery. In: Smyth, H., Hickey, A. (eds) Controlled Pulmonary Drug Delivery. Advances in Delivery Science and Technology. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9745-6_14

Download citation

Publish with us

Policies and ethics

Societies and partnerships

Search

Navigation